-
EP1527779
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP1527779
| EP1527779 - Sustained release ranolazine formulations [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 21.12.2012 Database last updated on 15.06.2024 | Most recent event Tooltip | 21.12.2012 | Application deemed to be withdrawn | published on 23.01.2013 [2013/04] | Applicant(s) | For all designated states Roche Palo Alto LLC 3431 Hillview Avenue Palo Alto California 94304-1397 / US | [2008/42] |
| Former [2005/18] | For all designated states CV THERAPEUTICS, INC. 3172 Porter Drive Palo Alto, CA 94304 / US | Inventor(s) | 01 /
Wolff, Andrew A. 1140 Lawton Street San Francisco CA 94122 / US | 02 /
Langridge, John Richard Schootsedijk 35 5491 TD Sint Oedenrode / NL | 03 /
Baker, Fiona 1 Afton Grove Fife KY11 4LE Dunfermline / GB | [2008/40] |
| Former [2005/18] | 01 /
Wolff, Andrew A. 1140 Lawton Street San Francisco CA 94122 / US | Representative(s) | Schnappauf, Georg, et al ZSP Patentanwälte PartG mbB Hansastraße 32 80686 München / DE | [N/P] |
| Former [2005/18] | Schnappauf, Georg Dr., et al Dr. Volker Vossius Patent- und Rechtsanwaltskanzlei Geibelstrasse 6 81679 München / DE | Application number, filing date | 04030151.7 | 09.09.1999 | [2005/18] | Priority number, date | US19980099804P | 10.09.1998 Original published format: US 99804 P | US19990321522 | 27.05.1999 Original published format: US 321522 | [2005/18] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP1527779 | Date: | 04.05.2005 | Language: | EN | [2005/18] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 15.03.2005 | Classification | IPC: | A61K31/495, A61K9/20 | [2005/18] | CPC: |
A61K9/2846 (EP,US);
A61K9/20 (KR);
A61K31/495 (EP,US);
A61K31/496 (EP,US);
A61K9/2027 (EP,US);
A61K9/205 (EP,US);
A61K9/2054 (EP,US);
A61K9/2077 (EP,US);
A61K9/2866 (EP,US);
| Designated contracting states | AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE [2005/18] | Extension states | AL | 20.12.2004 | LT | 20.12.2004 | LV | 20.12.2004 | MK | 20.12.2004 | RO | 20.12.2004 | SI | 20.12.2004 | Title | German: | Ranolazinhaltige Arzneimittel mit verzögerter Wirkstoffabgabe | [2005/18] | English: | Sustained release ranolazine formulations | [2005/18] | French: | compositions de ranolazine à libération contrôlée | [2005/18] | Examination procedure | 20.12.2004 | Examination requested [2005/18] | 09.02.2010 | Despatch of a communication from the examining division (Time limit: M04) | 04.06.2010 | Reply to a communication from the examining division | 13.03.2012 | Despatch of a communication from the examining division (Time limit: M04) | 24.07.2012 | Application deemed to be withdrawn, date of legal effect [2013/04] | 31.08.2012 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2013/04] | Parent application(s) Tooltip | EP99948196.3 / EP1096937 | Divisional application(s) | EP10011228.3 Application refused : 17.03.2011 | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP19990948196) is 18.06.2002 | Fees paid | Renewal fee | 20.12.2004 | Renewal fee patent year 03 | 20.12.2004 | Renewal fee patent year 04 | 20.12.2004 | Renewal fee patent year 05 | 20.12.2004 | Renewal fee patent year 06 | 21.09.2005 | Renewal fee patent year 07 | 27.09.2006 | Renewal fee patent year 08 | 26.09.2007 | Renewal fee patent year 09 | 25.09.2008 | Renewal fee patent year 10 | 25.09.2009 | Renewal fee patent year 11 | 27.09.2010 | Renewal fee patent year 12 | 26.09.2011 | Renewal fee patent year 13 | Penalty fee | Additional fee for renewal fee | 30.09.2012 | 14 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [AD]US4567264 (KLUGE ARTHUR F [US], et al) [AD] 1-34 * claim - ** examples 12,14 *; | [AD]EP0407780 (SYNTEX PHARMA LTD [GB]) [AD] 1-34 * claims 14,15 * * examples C,D *; | [AD]WO9426266 (SYNTEX INC [US]) [AD] 1-34 * claims 1,2,4-6,10-13,15 * * page 3, line 16 - line 19 * * page 4, line 37 - page 5, line 13 * * page 7, line 9 - line 11 * |